ArticlePhysics and imaging in radiation oncology2026
Feasibility of reduced setup uncertainty in intensity-modulated proton therapy for mediastinal lymphoma.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Mediastinal lymphoma patients are typically young and are at risk of long-term radiation-induced adverse events, making organ of interest (OOI) sparing a key objective of radiotherapy. This study investigated whether reducing setup uncertainty during robust intensity-modulated proton therapy (IMPT) planning is feasible without compromising target coverage and delivered dose robustness. Materials and methods: Ten consecutive mediastinal lymphoma patients treated with IMPT were retrospectively analyzed. Treatment plans were generated on the four-dimensional average computed tomography (4DCT) using a 5 mm setup uncertainty (clinical standard). Additional plans with 4 and 3 mm setup uncertainties were created using a dose-mimicking optimization approach while maintaining identical clinical priorities. Robustness was evaluated using a three-dimensional robustness evaluation method (3DREM) and a longitudinal four-dimensional robustness evaluation method (4DREM), incorporating setup and range variations, machine uncertainties, respiratory motion, and weekly anatomical changes. Results: All plans achieved adequate target coverage in the 3D-nominal and 4DREM voxel-wise mean dose distributions (V Conclusion: Reducing setup uncertainty during robust IMPT planning for mediastinal lymphoma patients was feasible and improved OOI sparing without compromising delivered dose robustness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.